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1. Introduction
General agreement prevails today on the contents of the term “amyloid”. It refers to “a
condition associated with a number of inherited and inflammatory disorders in which
extracellular deposits of fibrillar proteins are responsible for tissue damage and functional
compromise”, as defined in the textbook of pathology [1]. One and half centuries ago, in
contrast, the nature of amyloid was the very target of an academic dispute among the leading
scientists, European at those days. Curiously, the term “amyloid” has prevailed although in
the course of time the concept of amyloid has nearly turned upside down.
2. Origin of amyloid: Matthias Schleiden and botany
The term “amyloid” was brought in the scientific literature by the German botanist Matthias
Schleiden (1804 - 1881). Schleiden was born in Hamburg as the son of a Hamburger physician.
He first studied laws in Heidelberg and received his pHD in 1826. However, working as a
lawyer felt unsatisfactory to him and he turned to study medicine in 1832, in Göttingen and
Berlin. Schleiden oriented to botany, microscopy and anatomy, with a special interest in the
chemical and anatomical composition of plant cell, and received his second PhD in 1839. One
of Schleiden’s major ideas was to apply the iodine-sulphuric acid test for starch in plants. This
test was originally described in 1814 by Colin and Gaultier de Claubry to show the blue staining
reaction of starch with iodine and sulphuric acid [2]. Schleiden presented his discoveries at the
scientific meetings of the “Gesellschaft Naturforschender Freunde” and reported on the
application of the iodine-sulphuric acid test on plants on the 20th February, 1838 (in: Ostwalds
klassiker der exakten Wissenschaften, band 275 Verlag Harri Deutsch (Klassische Schriften zur
zellenlehre. Matthias Jacob Scleiden, Theodor Schwann, Max Schulze, text in German), cited
in [3]. Scleiden’s original interpretation was that the reaction demonstrated the transformation
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of the plant material into starch [4]. Schleiden published his several botanical findings in the
book form in 1842-43, with the title “Grundzige der wissenschaftlichen Botanik”. It is remark‐
able that the 2nd and 3rd editions of the book, subtitled as “Die Botanik als inductive Wissen‐
schaft behandelt” were also translated in English in 1849, with the name “Principles of
Scientific Botany” and “Botany as an Inductive Science”, reflecting the attraction that Schlei‐
den’s observations woke also outside Germany. In the above mentioned book Schleiden first
time uses the term “amyloid” for starch, referring to“starch-like”. The word itself stems from
the latin word “amylym” for starch. Schleiden describes “amyloid” to represent “a normal
amylaceous constituent in plants” [2], as shown in the straight citing from the English
translation of the book [5] below.
“Amyloid is, when dry, a cartilaginous, but moist, gelatinous, clear, transparent body, soluble in boiling water, strong
acids, and caustic alkalies, but not in ether and alcohol in a concentrated state. It is coloured blue by iodine, and the
combination is soluble in water, giving it a golden-yellow colour. It is found only in the layers of the primary cell-
membrane. There is no chemical analysis of this substance. It has been found at present only in the cotyledon-cells of
Schotia latifolia,S. speciosa, Hymencea Courbaril, Mucuna urens, M. gigantea, and Tamarindusindica.“
The application of the iodine-sulphuric acid test on plants was not the most remarkable among
Schleiden’s scientific discoveries. Based on his interest in microscopic studies he got the unique
idea that plants are made of cells, and that the growth of plants depends on the production of
new cells. To get to this idea Schleiden was also lucky. In Berlin he had met Theodor Schwann
(1810 - 1882), another great scientist of those days who had made similar observations in
animals [6]. The published observations of Schleiden (1838) and Schwann (1839) form the basis
for the unified “cell theory”, applicable to all living organisms. During the same time (1839)
the French chemist Anselme Payen (1795 - 1878) described a substance in woods that resembled
starch. This substance reacted with iodine-sulphuric acid test similarly to starch, and Payen
named it "cellulose". The iodine-sulphuric acid reaction became later on a standard procedure
used by botanists to demonstrate the presence of cellulose in woods [4].
It is well possible that amyloid deposits have been described even earlier, in the reports on
human autopsy cases with homogenous material in liver or spleen tissue [2], probably
representing amyloid. The first observation stems from the year 1639, described by Nicolaus
Fontanus.
3. The term “amyloid” in the medical literature: Rudolf Virchow
Whereas Matthias Schleiden was the first to use the term “amyloid” in botanics, it was the
German pathologist Rudolf Virchow (1804 - 1881) who applied it in the medical literature.
Virchow studied medicine and anatomy in Berlin and Würzburg, and was graduated in 1843.
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Virchow was interested in microscopic studies, similarly to Schleiden. Virchow used the word
“amyloid” first time in 1854 in his publication “Über eine in Gehirn und Rückenmark des
Menschen aufgefundene Substanz mit der chemischen Reaction der Cellulose”, in Virchow’s
Archiv für Pathologische Anatomie and Physiologie und fur klinische Medicin. Berlin 6;
354-368; 1854 [7]. In this paper Virchow described the small round deposits in the nervous
system (Figure 1) with the mention that those structures showed the same color reaction with
iodine and sulfuric acid, i.e. a change from brown to blue, typical to starch. Therefore, Virchow
was convinced that those structures were identical to starch [8]. Virchow named those
structures “corpora amylacea”, similarly to Schleiden (the name based on the Latin term
“amylum” for starch, see previously). Later Virchow applied the iodine sulphuric acid test to
other tissues infiltrated with amyloid. The representatives of the French and British Schools
instead considered amyloid to be more closely related to cellulose [2]. They use the name
“lardaceous” (based on the bacon-like appearance of the tissue, French School) and “waxy”
(based on the homogeneity of the material, British School). They could also use the term “sago”
(a sweet substance in certain palm species).
Figure 1. Corpora amylacea (arrows) stain blue in H&E (A) and brown in methenamine-silver (B) stain which also re‐
veals a few senile plaques of diffuse type (B). Diffuse plaques do not contain amyloid. The patient was 104-year old
female suffering from vascular dementia. Original magnification x 200.
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Virchow developed an observational and experimental view on medical sciences. In this
regard he resembled the French and British scientists at that time but contrasted to the more
speculative German scientific tradition. As Virchow’s writings received an unfavorable
attention in German journals he decided to found in 1847 a journal of his own “Archiv für
pathologische Anatomie und Physiologie und für klinische Medizin” with another German pathol‐
ogist, Benno Reinhardt. The bearing idea of the new journal was not to publish papers
containing “outdated, untested, dogmatic or speculative ideas”. After Reinhardt's death in
1852 Virchow edited the paper alone, with the name “Virchow's Archives”, a world-famous
and respected journal still today.
Virchow’s investigations in pathology extended to several other clinically significant issues.
For instance, he discovered the mechanism of thromboembolism and developed the standard
method of autopsy, as described in “The handbook on special pathology and therapeutics” in
1854. Further, in addition to Schleiden and Schwann, Virchow was the third scientist who has
been nominated as an inventor of the “cell theory”. He applied the concept in humans and
published it in “Cellular pathology” in 1859. Yet, the probably most significant of Virchow’s
ideas was that he understood to combine the macroscopic and microscopic pathologies with
clinical manifestations of disease [9].
Virchow was not only a pathologist. His interest and knowledge extended to anthropology,
archeology, politics and social sciences [10]. For instance, Virchow established the first hospital
trains bringing medicine in the battlefields, and he also was the first to understand the influence
of poor hygiene on the spread of contagious illnesses. Political and social activities combined
with huge scientific career brought to Virchow the status as the world-renowned physician
and “Father of pathology”.
4. The end of the 1800’s: Progress in the staining methods to detect amyloid
A new insight into the biochemical character of amyloid was presented in 1859 when the
prominent German chemist August Kekulé (1829 - 1896) reported on the high proportion of
nitrogen in organs infiltrated with amyloid [2,11]. Kekulé assumpted that the material mainly
represented “albumoid” compounds. In addition, he did not find material corresponding
chemically to “amylon” or cellulose.” Virchow never agreed with Kekulé, criticizing his
method to analyze the whole tissue specimens (e.g. liver). After Virchow’s opinion, convincing
results necessitated a method to isolate the amyloid substance first [2]. Indeed, also in this he
was ahead of his time. After more than one hundred years other constituents such as glyco‐
saminoglycans and heparan sulphate [12,13] and chondroitin sulphate -containing proteogly‐
cans [14,15] were identified as additional, albeit minor components of amyloid deposits [16].
In contrast to Virchow, Kekulé’s observation on high nitrogen contents of amyloid were
accepted by several scientists, including the British physician Samuel Wilks (1824 - 1919) who
had collected more than 60 cases with the white, “stony”, “gelatinous” or “lardaceous” visceral
material, i.e. amyloid detected at the autopsy [2]. George Budd, another British internist (1808
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- 1882) actually got the same result than Kekulé when analyzing the chemical composition of
a pale autopsy liver [2].
There was another novel invention that Virchow did not accept: the metachromatic stains. In
1875 three scientists; the French pathologist and histologist Victor Cornil (1837 - 1908) in Paris,
the Austrian anatomist Richard Heschl (1824 - 1881) in Vienna and Rudolf Jürgens in Berlin
described independently the usefulness of methylviolet stain to detect amyloid. Already next
year, in 1876, Soyka reported having found amyloid in the cardiac tissue with the use of this
new method (Soyka J. Prag Med Wschr 1: 165, 1876; cited in Hodgkinson and Buerger [17,18]).
William Ackroyd and Paul Ehrlich described methylviolet stain as “metachromatic” in 1878.
Metachromatic stains challenged Virchow’s iodine sulfuric acid test for decades [2] but were
eventually replaced by Congo red.
5. Development of contemporary staining methods: Congo red dye and
fluorescence microscopy
Reactivity with Congo red stain or “Congophilia with apple green birefringence” was the first
criterion for amyloid [11], introduced by the Belgian Physician Paul Divry (Divry P. Etude
histo-chimique des plaques seniles. J de Neurologie et de Psychiatrie 27:643-57, 1927, cited in
Sipe [11]). Congo red dye itself was invented by the German chemist Paul Böttiger in 1884
(Böttiger P. Deutsches Reich’s Patent 28753, August 20, 1884, cited in Frid [19]). Congo red is
an aniline dye, originally created and used for staining textiles. Böttiger developed the first
“direct” dye that did not require additional substances for fixation to the textile fibers. The
owner of the patent, the AGFA Corporation developed the name "Congo" to the new dye after
the diplomatic conference that was ongoing in Berlin just at that time (1884 - 1885). The goal
of the “Congo conference” was to mediate a trade dispute between several European colonial
powers in the Congo River Basin in Central Africa [2,20]. The name “Congo” referred to an
exotic place that was on the tip of the lips, and proved to be effective for marketing purposes
[2,20]. In addition to staining textiles Congo red was actually used to stain tissues already in
1886 [20]. However, it was not until in the year 1922 when the young German chemist Herman
Bennhold discovered the capacity of Congo red to bind to amyloid (Bennhold H. Eine
spezifische Amyloidfärbung mit Kongorot. Münchener Medizinische Wochenschrift (Novem‐
ber):1537-1538, 1922; cited in Kyle [2]). In 1962 Puchtler described the renewed method for the
use of Congo red in histological preparations [21].
The Puchtler modification [21] of Congo red staining is widely used in pathology as the first
step in detecting amyloid in histological specimens. Of course, individual laboratories may
apply their own variant of the method. Congo red staining is also applicable to frozen sections
and for staining devices. In the diagnostic purposes the formalin-fixed histological samples
are generally embedded in paraffin, sectioned 5-8 μm thick slices, stained with Congo red, and
viewed in a light microscope under polarized light in which amyloid can be seen as red to
green birefringent homogeneous material.
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(Figure 2). Interestingly, the light microscope finding has been observed to vary in different
types of transthyretin (TTR)-related amyloidosis and accordingly the distribution into two
different histological patterns of amyloid deposition (designed as A and B) has been proposed
[22]. In pattern A, seen in senile systemic amyloidosis (SSA) and in some cases with TTR-related
familial amyloidosis, there is weakly congophilic, homogenous amyloid material that is patchy
distributed. In pattern B, detected in a part of patients with TTR-related familial disease,
strongly congophilic amyloid appears as thin streaks. Thus, the biochemical structure of
amyloid fibrils can be transmitted to the microscopic finding.
Figure 2. The red colour (A) of amyloid in the cardiac tissue of a patient with senile systemic amyloidosis (SSA) gradu‐
ally (B,C) turns to green (D) in the polarized light. Original magnification x 400.
The chemical name of Congo red, also known as ”direct red”, “direct red 28”, or “cotton red”,
is 3,3΄-[(1,1´-biphenyl)-4,4´-diylbis(azo)] bis-(4-amino-1-naphtalene acid) disodium salt
(C32H22N6O6S2 2Na). It is a symmetrical molecule with the molecular weight of 696.7 g/mol and
the diameter approximately 21Å [23]. The molecule has a hydrophobic center composed of
two phenyl rings that are linked via diazo bonds to two charged terminal naphtalene moieties.
The terminal parts of Congo red contain sulphonic acid and amine groups. Congo red exists
in chinone form in acidic solution, and in sulphonazo form in basic solution, changing the color
from blue (below pH 3) to red (above pH 5). Thus, Congo red can be used as a pH indicator
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as well. The binding of Congo red to amyloid induces a characteristic shift in the maximal
optical absorbance of the molecule from 490 nm to 540 nm. The mechanisms of interaction
between Congo red and amyloid fibrils has been intensively studied [24,25] but the process is
not completely understood [19]. Congo red binding has been assumed to depend on the
secondary, β-pleated configuration of the fibril, possibly mediated by hydrophobic interac‐
tions of the benzidine centers as well as the electrostatically charged terminal groups [19].
Amyloid can also be visualized using the fluorescence microscope. Fluorescence microscope
is a light microscope used to study the properties of organic and inorganic substances with the
aid of the phenomena of fluorescence and phosphorescence. The component of interest in the
specimen is labeled with a fluorescent molecule, the “fluorophore”. Amyloid can be detected
using thioflavin stains (Thioflavin-T or -S) which emit green fluorescence when they are bound
to amyloid. Thioflavin-T (Basic Yellow 1 or CI 49005) is a benzothiazole salt, obtained by
methylating dehydrothiotoluidine with methanol in the presence of hydrochloric acid. When
the dye binds to β sheets it undergoes a 120 nm red shift of its excitation spectrum that may
selectively be excitated at 450 nm, resulting in a fluorescence signal at 482 nm. Thioflavin-S is
a mixture of compounds resulting from the methylation of dehydrothiotoluidine with
sulphonic acid. The fluorescence method is specific for amyloid similarly to Congo red [26]
and very sensitive. The disappearance of fluorescence during time can be regarded a disad‐
vantage of the method, because the reaction cannot be re-examined later.
6. The beginning of the 1900’s: Alzheimer’s disease and associated
pathologies
In 1907, Aloysius (Alois) Alzheimer described "senile" plaques and neurofibrillary tangles in
a demented patient. Today we know that the plaques represent extracellular amyloid derived
from amyloid beta (Aβ) protein whereas the neurofibrillary tangles represent intracellular
amyloid formed on tau protein.
Alzheimer (1864 -1915) was German psychiatrist, born in Bavaria. He got his medical education
at the universities of Tübingen and also in Berlin and Würzburg, similarly to Virchow, to
receive his medical degree in 1887. Soon thereafter he began to work in a mental asylum “die
Städtische Anstalt für Irre und Epileptische” in Frankfurt am Main. Alzheimer’s scientific
interest focused on pathology of the nervous system, especially anatomy of the cerebral cortex.
He collaborated with the neuropathologist Franz Nissl (1860 - 1919) and learned Nissl's method
of silver staining of the histological sections. In the year 1901 Alzheimer happened to get the
51 -year old Mrs. Auguste Deter to be his patient at the Frankfurt Asylum. Mrs. Deter had a
very unusual clinical picture with loss of short-term memory and odd behavioral symptoms.
In 1902 Alzheimer moved to work with his colleague, another German psychiatrist Emil
Kraepelin (1856 - 1926) at the University of Heidelberg. Kraepelin had, similarly to Alzheimer,
special interest in neuropathology. Both moved to Munich next year. Mrs Deter died in 1906
in Frankfurt, and Alzheimer decided to bring her brain and medical records to Munich for
neuropathological study. He grasped to apply Nissl's method of silver staining on the
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histological sections of Mrs. Deter’s brains, and thereby identified the neurofibrillary deposits
in the atrophic brain. The first report of the extraordinary pathological findings was presented
in the same year at the University of Tübingen, prior to the appearance of the publication in
1907 (Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift
für Psychtiatrie und Psychisch-gerichtliche Medizin. 1907 Jan; 64:146-8).
The original histological sections on which Alzheimer based his description were rediscovered
in the 1990ies in Munich. This gave the unique opportunity to re-evaluate his work [27]. Silver
stains have been used to diagnose Alzheimer’s disease (AD) during decades and the original
observations made by Alzheimer’s and Kraepelin are valid even today. Quite recently,
techniques using the immunohistochemistry (IHC) -based techniques in the diagnosis of AD
pathology have also been introduced [28]. Alzheimer’s neuropathological discoveries were
not restricted to AD pathology. For example, he also described the loss of nerve cells in the
corpus striatum in Huntington's disease and brain changes in epilepsy [29].
Mrs. Deter suffered from a syndrome that is called today as presenile dementia. Presenile
dementias form a group of hereditary dementia syndromes which are often autosomally
dominantly inherited. It has turned out that presenile dementia syndrome is quite common in
the population called Volga Germans (VG). VG stems from people who emigrated in the 1760
s from the German Hesse area around Frankfurt to the southern Volga region in Russia. During
the late 19th and early 20th centuries many of the descendants of VG emigrated to US. Presenile
dementia of the VG is due to the mutation N141I in the gene for presenilin (PSEN) 2 [30].
Interestingly, neuropathology of the brains of subjects with this mutation is similar to Mrs.
Deter’s case [27]. Therefore, especially as Mrs. Deter was living in the Hesse area in Germany,
an idea was got that she would have belonged to the population of VG. Mrs. Deter’s brain
tissue was tested for the presence of the PSEN 2 mutation – but the result was negative [31].
Yet, this does not preclude that Mrs. Deter would have had a different mutation in PSEN 2 or
a mutation in other genes such as PSEN 1 or APP.
Although the diagnosis of Mrs. Deter is still open, Alzheimer’s paper was a starting point to
enormous amounts of experimental and applied investigations of AD, an old age associated
dementia syndrome. The disease belongs to the major causes of death in the western world,
and it is estimated that about 24 million people suffer from it worldwide [32]. In spite of the
huge work, the etiology of AD is still uncertain. Several hypotheses have been proposed [33],
of which the “amyloid cascade hypothesis” by John Hardy and Gerald Higgins [34] has maybe
got the greatest attention. The theory has recently also been criticized [35] as many therapeutic
attempts based on it have failed [36].
The first descriptions of AD pathology were based on silver staining (Figure 3A) without no
idea about the biochemical composition (Figure 3B) or relationship to amyloid of such
structures (Figure 3C,D). Plaque amyloid however was discovered relatively soon (in 1927, see
previously) by Divry after Bennhod had published his application of Congo red in tissue (in
1922, see previously). Cerebrovascular amyloid (cerebral amyloid angiopathy, CAA), detect‐
able in 80-90% in the brains of patients with AD was first time reported by Greek Pantelakis
in 1954 [37].
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Figure 3. A senile plaque with amyloid core stained with methenamine-silver (A), immunohistochemistry against Aβ
(B) and Congo red (C without and D with polarization) stains. Original magnification x 600.
7. Identification and extraction of the amyloid fibril
After the 2nd world war amyloid research stretched from Europe to include also Northern America
and Japan. A substantial advance in the field took place in the late fifties. Two American
researchers, Alan S Cohen from Harvard Medical School in Boston and Evan Calkins from
Massachusetts General Hospital reported on the fibrillary structures in the samples of several
types of amyloids in 1959 using electron microscopy (Cohen AS and Calcins E. Electron microscop‐
ic observations on a fibrous component in amyloid of diverse origins. Nature 183 1202-3, 1959;
cited in Vinters [38]). Several attempts followed to isolate the fibrils from tissues and organs.
Cohen and Calkins themselves described the first extraction method. It consisted of gentle
physical separation and homogenization of the material in saline, followed by low-speed
centrifugation. This yielded a layer of fibrils not present in the sedimentation pellets of normal
tissues and demonstrated a green birefringence in polarized light after staining with Congo red
[39]. The next method was published by George Glenner and Howard Bladen (NIA, Bethesda,
Maryland). They had extracted amyloid fibrils using alkaline sodium glycinate in 1966 [40].
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A significant step forward took place when M Pras (originally from the Tel Hashomer Hospital,
Tel Aviv, Israel) and colleagues from New York University School of Medicine described the
method to extract proteins from amyloid-laden tissues using water [41]. Spleen tissue from a
deceased patient with “primary” (i.e. AA) amyloidosis was homogenized with physiological
saline (NaCl), and the mixture was centrifuged. The sediment was next homogenized with
NaCl several times to remove most of the soluble proteins and other soluble materials. Salt
was then removed by homogenizing the residue in distilled water, followed by centrifugation
of the suspension. Lastly, the residue was homogenized in distilled water and centrifuged four
times to give a supernatant rich in protein. Adding Congo red dye and NaCl then resulted in
a gelatinous precipitate with the typical green birefringence, demonstrating that the superna‐
tant represented soluble amyloid.
The “water extraction method” of Pras has been widely used to extract almost all types of
amyloid except for Aβ and prion protein amyloid [42,43]. The method was revolutionary in
amyloid research as it enabled (1) identification of the β-pleated sheet configuration of amyloid
proteins and (2) discovery of the biochemical structure of those proteins.
8. The β-pleated sheet configuration
In nature, most proteins have both α-helix and β-pleated sheet secondary structure. In the
amyloid form, the proteins are mostly in the β-pleated sheet conformation though not
exclusively. Factors that may influence changes in the spatial form of proteins include
increased protein content, low pH, metal ions proteins that are associated with amyloid
deposits but are not part of the insoluble fibrils themselves, also called ” chaperones” [44]. The
secondary structure of amyloid consists of the polypeptide backbone, mostly in the β-pleated
sheet conformation, oriented perpendicular to the fibril axis. This β-pleated sheet structure
was revealed by X-ray diffraction analysis of isolated amyloid protein fibrils by Eanes and
Glenner in 1968 [45-47].
9. Identification of the different amyloid proteins
The major consequence of the invention of the water extraction method of Pras was the
identification of the biochemical composition of several kinds of amyloids. Glenner and his
colleagues soon applied the method to the “primary” (today: AL) amyloidosis [48] and found
the relationship between this amyloidosis and immunoglobulin light chains. AL amyloidosis
is a neoplastic disease and belongs to the clinically most significant amyloid -related conditions.
During the subsequent years, a long list of amyloid proteins was identified one after another.
Inflammation-associated  amyloidosis,  previously  called  the  “secondary”  and  today  AA
amyloidosis, was shown to be caused by amyloid protein A, an acute phase protein in 1972 [49].
Serum protein A was thereafter soon identified in blood [50,51]. In 1978, prealbumin (transthyr‐
etin, TTR) was found to be the protein constituent of amyloid deposits in Portuguese familial
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amyloid polyneuropathy (FAP) [52], the clinical condition having been described already in
1951 (Corino de Andrade, M. Preliminary note on an unusual form of peripheral neuropathy.
Rev Neurol (Paris) 85: 302-6, 1951; cited in Kyle [2]). Similar diseases were found especially in
Japan and Sweden in the subsequent decades. The Finnish type of familial amyloidosis, today
known as AGel amyloidosis, was described in 1969 by the Finnish ophthalmologist Jouko
Meretoja [53]. In 1980, TTR was characterized as the amyloid protein also in “senile cardiac
amyloidosis” (SCA) [54], later renamed as senile systemic amyloidosis (SSA) [55,56]. In 1983,
the Icelandic type of familial cerebral amyloid angiopathy (HCHWA-I) was found to be related
to cystatin-C protein [57]. Next year, 1984, the first report on the AD-associated Aβ protein was
published two Glenner and Wong who identified Aβ in the cerebrovascular tissue [58]. Colin
Masters (Australian), Konrad Beyreuther (German) and colleagues described the same protein
one year later, in 1985, in the plaques (Figure 3B). Japanese Fumitage Gejyo described beta 2 -
microglobulin as the amyloid fibril protein in the dialysis-related amyloid arthropathy in the
same year [60]. Tau protein of the neurofibrillary tangles was identified in 1986 in the laborato‐
ry of Henryk Wisniewsky in New York by Inge Grundke-Iqbal and colleagues [61].
The nature of islet amyloid polypeptide (IAPP) was discovered by Swedish pathologist Per
Westermark from University of Uppsala and his colleagues in 1986 [62,63]. In 1988, apolipo‐
protein A1 (APOA1) was characterized as the amyloid protein in the hereditary amyloid
disease in Iowa, USA [64]. In 1990, two groups discovered independently that amyloid fibril
protein in the Finnish (AGel) amyloidosis was related to gelsolin [65,66] and identified the
causative Asn-187 mutation in the gene for gelsolin [67,68]. The first description of a genetic
cause for a hereditary amyloid disease was already published several years earlier, as the
Japanese Satoru Tawara and colleagues identified the point mutation in the gene coding for
TTR leading to the substitution of methionine instead of valine at position 30 in TTR-related
FAP in 1983 [69]. Development of the polymerase chain reaction (PCR) –based techniques have
accelerated the identification of mutations in the genes of the amyloidogenic proteins, and
today more than one hundred different mutations have been described in the TTR gene. Most
of the mutations lead to clinical disease with the deposition of amyloid in different organs.
In the past two decades three different proteins were characterized describing three novel
different familial amyloid diseases with a preference for renal manifestation: fibrinogen A-α
chain [70], lysozyme [71] and apolipoprotein AII [72]. The last identified amyloid fibril protein,
also presenting with renal amyloidosis especially in Mexican Americans, was leucocyte
chemotactic factor 2 [73].
10. Prion diseases
Characterization of the prion protein (PrP) in 1982 [74] opened up a new perspective in the
amyloid reseach. Scrapie, a prion disease in sheeps and cows, was described in Spanish merino
sheeps already in 1732 [75] but it took two and a half centuries to detect the causative agent.
Scrapie belongs to prion diseases, also referred to “transmissible protein misfolding disorders”
[76]. The highest degree in the conformational shift from α-helix to β-sheet structure occurs in
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the genetically determined form (Gerstmann-Straussler- Scheinken disease) and in PrP -
associated CAA [77].
Prion diseases occur in several mammalian species and can be sporadic, hereditary, or
acquired. The disease exists in nine different types in humans. The first known descriptions
of human prion disease appeared independently in 1920 and 1921 by Creuzfeld and (Creutz‐
feldt HG: Über eine eigenartige herdformige erkrankung des Zentralnervensystems. Z
gesamte Neurol Psychiatr 1920, 57: 1-19) and Jacob (Jacob A: Über eigenartige Erkrankungen
des Zentralnervensystems mit bemerkenswertem anatomischen Befunde. (Spastische Pseu‐
doskleros- Encephalomyelopathie mit disseminierten Degenerationsherden). Z Gesamte
Neurol Psychiatr 1921, 64: 147-228.), cited in Imram [76]). This has formed the basis for the
contemporary name of the disease: “sporadic Creutzfeldt –Jacob’s disease”.
Two Australian anthropologists, Ronald and Catherine Berndt, were the first to describe the
peculiar disease occurring in the Fore linguistic group of people in the Australian Pretectorate
of New Guinea, today Papua-New Guinea. Vincent Zigas, the district medical officer started
to study the disease in 1957 with the young American virologist and pediatrician Carleton
Gajdusek who was interested in infectious diseases. The clinical picture of the disease, as
described in the article: “Degenerative Disease of the Central Nervous System in New Guinea
— The Endemic Occurrence of Kuru in the Native Population” [78], cited in Libersky [79],
consisted of headache and pain, cerebellar ataxia, tremors, shivering and choreiform or
athetoid movements. The disease, named as “kuru”, occurred exclusively in that Fore linguistic
group people and was due to the ritualistic cannibalism (“transumption”). Kuru was neuro‐
pathologically characterized with neuronal degeneration, myelin degeneration, astroglial and
microglial proliferation and plaque formations [80]. Interestingly, another human prion
disease presenting with similar plaques occurred in Western Europe four decades later. The
disease, first reported in UK in 1996 by British investigators and called as “variant CJD” [81]
however manifested differently. The typical features of variant CJD include agitation, aggres‐
sion, apathy and paranoid delusions [81]. BSE (Bovine spongiform encephalopathy) prions
were soon shown to be causally linked with variant CJD [82].
The American scientist Stanley Prusiner purified the prion protein (PrP Scr) from sheep in 1982
[83]. The name “prion” was based on the letters of the word Proteinaceus. Prusiner assumed that
PrP would act solely in the protein level without influence of any genetic material, as it had been
proposed several years previously [84]. This and several other several issues are still open, such
as if there are factors rendering cells capable of replicating prions and propagating them to the
nervous system, and if PrP is fully infective without any cofactors [85]. Gajdusek (in 1976) and
Prusiner (in 1997) were honored with Nobel Prize in Medicine for their work in prion diseases.
11. Nomenclature
The modern nomenclature of different types of amyloids (Table 1) is based on the amyloid




Precursor protein Type Syndrome (Involved tissue)
AA (Apo)serum AA S Reactive, previously: “secondary”
AANF Atrial natriuretic factor L (Cardiac atria)
AApoAI Apolipoprotein AI S, L Familial (aorta, meniscus)
AApoAII Apolipoprotein AII S Familial
AApoAIV Apolipoprotein AIV S Sporadic, aging
ABri ABriPP S Familial dementia, British
ACal (Pro)calcitonin L C-cell thyroid tumors
ACys Cystatin C S Familial
ADan ADanPP L Familial dementia, Danish
AFib Fibrinogen α-chain S Familial
AGel Gelsolin S Familial, previously: “Finnish”
AH Immunoglobulin heavy chain S; L Myeloma-associated, previously: “primary”
AIAPP Islet amyloid polypeptide L Insulinomas, aging, previously: “amylin” (Islets
of Langerhans)
AIns Insulin L Iatrogenic
AKer Kerato-epithelin L Familial (cornea)
AL Immunoglobulin light chain S; L Myeloma-associated, previously: “primary”
ALac Lactoferrin L (Cornea)
ALect2 Leukocyte chemotactic factor 2 S Mainly kidney
ALys Lyspzyme S Familial




APro Prolactin L Prolactinomas, aging (pituitary gland)
APrP Prion protein L Spongiform encephalopathies (brain)
ASemI Semenogelin I L (Vesicula seminalis)
ATTR Transthyretin S,L? Familial, SSA (localized: tenosynovium)
Aβ Aβ protein precursor (AβPP) L Aging, AD, CAA
Aβ2M β2-microglobulin S; L? Hemodialysis-associated (localized: joints)
S = systemic; L = localized; SSA = senile systemic amyloidosis; AD = Alzheimer’s disease; CAA = cerebral amyloid
angiopathy.
Table 1. Human amyloid fibril proteins and their precursors.
Title: “Amyloid” — Historical Aspects
http://dx.doi.org/10.5772/53423
15
in Helsinki, Finland, in connection with the 1st International Symposium on Amyloidosis. The
1st official nomenclature committee was founded at the 3rd international symposium on
amyloidosis in Povoa de Varzim, Portugal (1979). Thereafter the committee (the Nomenclature
Committee of the International Society of Amyloidosis) has met several times to create the
official nomenclature lists for each types of amyloid. The last meeting took place in 2010 in
Rome, Italy (2010), in conjunction with the 12th International Symposium on Amyloidosis
[86]. The reports of the meetings are published in “Amyloid”, the official journal of amyloid
diseases.
To be included in the official nomenclature list, the amyloid fibril protein fibril must have been
unambiguosly characterized and described in a peer-reviewed journal. The present nomen‐
clature list contains 27 fibril proteins capable to cause human disease. Nine of them have been
tested in animals. There are also at least and six proteins appearing as intracellular inclusions,
with all or some properties of amyloid [86].
12. The clinical diagnosis of amyloidosis
The diagnosis of the depositon of amyloid in diverse clinical conditions has traditionally
needed a tissue sample stained with Congo red or thioflavin compounds, followed by the
definition of the fibril protein using the IHC-based techniques. These techniques, using
commercially available antibodies are quite well applicable in most of the clinically significant
amyloid diseases.
The usage of radiological techniques to detect amyloid deposits started in 1988 when Philip
Hawkins (London) reported on the usage of in vivo radiological techniques using the 123I
labeled serum amyloid P component (SAP) in mice [87]. Two years later the same technique
was applied successfully in humans [88]. Recently, antibodies to human SAP molecule were
even shown to have potential therapeutic properties in both mice and humans [89], based on
the ability of the antibodies to trigger a giant-cell reaction to eliminate visceral amyloid
deposits. Another milestone in the radiological diagnostics of amyloid diseases was the
discovery by Klunk and colleagues (University of Pittsburgh, US) of the 11C-labeled PET tracer
“Pittsburgh compound B” (PiB) to bind selectively to fibrillar Aβ [90]. This made it possible
to reveal amyloid pathology noninvasively in subjects with AD pathology. Yet, the half-time
(T1/2) of 11C is very short (about 20 min) and therefore not applicable in clinical use. The recent
invention of a comparable 18F-labeled tracer with much longer T1/2 (110 min) is expected to
expand the applicability of PET in a larger number of patients. Of the potential 18F-labeled
tracers tested, 18F-AV-45[91] seems to be the most promising [92].
13. Conclusion
The concept of amyloid has transformed several times during the nearly two century long
research history of the issue. It is now clear that the cerebral corpora amylacea that inspired
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Virchow so greatly are mostly composed of glycogen-like substances with sulfate and
phosphate groups. In this regard, Virchow actually was right. On the other hand, it has also
turned out that those structures do not represent amyloid. Therefore, it can be asked why the
term “amyloid” still has prevailed. The most apparent explanation is Virchow’s standing as
one of the most valued scientists of his time and probably also the iodine staining that was
used for a long time as the diagnostic test for amyloid [93].
Amyloid research has traditionally related to the diagnosis and clinical manifestations of the
deposition of amyloid in the tissues and organs in diverse disease conditions. Applications in
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